Greenwich LifeSciences Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Snehal Patel
Chief executive officer
US$2.8m
Total compensation
| CEO salary percentage | 20.2% |
| CEO tenure | 14.3yrs |
| CEO ownership | 41.5% |
| Management average tenure | no data |
| Board average tenure | 14.3yrs |
Recent management updates
Recent updates
Here's Why We're Not Too Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Situation
Jan 12
We're Not Very Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Rate
Jan 29Greenwich LifeSciences: Persevering CEO And Interesting Data
Sep 06Greenwich LifeSciences halts stock buyback program
Jul 11Greenwich LifeSciences: A First Look
May 19Greenwich LifeSciences: Insider Buying And Buybacks Telegraph This Company's Vast Potential
Apr 21Companies Like Greenwich LifeSciences (NASDAQ:GLSI) Are In A Position To Invest In Growth
Feb 01We Think Greenwich LifeSciences (NASDAQ:GLSI) Can Afford To Drive Business Growth
Sep 30We're Not Very Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Rate
Apr 04Are Insiders Buying Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock?
Feb 16
What Is The Ownership Structure Like For Greenwich LifeSciences, Inc. (NASDAQ:GLSI)?
Dec 25Greenwich LifeSciences: Optimism On 'GP2' Breast Cancer Immunotherapy Candidate
Dec 23Greenwich LifeSciences under stress on pricing upsized $26.4M equity offering
Dec 18Greenwich LifeSciences inks deal with Westport Bio for pre-clinical coronavirus vaccine candidates
Dec 15Greenwich LifeSciences trebles in value as breast cancer therapy shines in mid-stage trial
Dec 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$3m | US$557k | -US$9m |
| Sep 30 2023 | n/a | n/a | -US$9m |
| Jun 30 2023 | n/a | n/a | -US$9m |
| Mar 31 2023 | n/a | n/a | -US$8m |
| Dec 31 2022 | US$2m | US$506k | -US$8m |
| Sep 30 2022 | n/a | n/a | -US$7m |
| Jun 30 2022 | n/a | n/a | -US$6m |
| Mar 31 2022 | n/a | n/a | -US$6m |
| Dec 31 2021 | US$1m | US$450k | -US$5m |
| Sep 30 2021 | n/a | n/a | -US$3m |
| Jun 30 2021 | n/a | n/a | -US$3m |
| Mar 31 2021 | n/a | n/a | -US$2m |
| Dec 31 2020 | US$999k | US$115k | -US$2m |
| Sep 30 2020 | n/a | n/a | -US$1m |
| Jun 30 2020 | n/a | n/a | -US$1m |
| Mar 31 2020 | n/a | n/a | -US$4m |
| Dec 31 2019 | US$139k | n/a | -US$3m |
Compensation vs Market: Snehal's total compensation ($USD2.75M) is above average for companies of similar size in the US market ($USD1.59M).
Compensation vs Earnings: Snehal's compensation has increased whilst the company is unprofitable.
CEO
Snehal Patel (59 yo)
14.3yrs
Tenure
US$2,750,029
Compensation
Mr. Snehal S. Patel has been Chief Executive Officer of Greenwich Lifesciences Inc. since June 2016 and has been Chief Financial Officer and Director since February 2010. He serves as Managing Director at...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, CFO & Director | 14.3yrs | US$2.75m | 41.55% $ 72.9m | |
| Founder & Independent Director | 17.8yrs | US$65.64k | 2.43% $ 4.3m | |
| Chief Medical Officer & Director | 4.7yrs | no data | 0.70% $ 1.2m | |
| Independent Chairman of the Board | 15.3yrs | US$98.39k | 4.82% $ 8.5m | |
| Independent Director | 4.7yrs | US$65.64k | 3.09% $ 5.4m |
14.3yrs
Average Tenure
72yo
Average Age
Experienced Board: GLSI's board of directors are seasoned and experienced ( 14.3 years average tenure).